SDZ 220-581

Key Product Details

Product Description

SDZ 220-581 is a competitive NMDA receptor antagonist (pK_i = 7.7). Centrally active following oral administration (ED₅₀ < 3.2 mg/kg for protection against MES-induced seizures).

Licensing Information

Sold with the permission of Novartis Pharma AG

Product Specifications for SDZ 220-581

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SDZ 220-581

The following data is based on the product molecular weight 369.74.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

11 10 9 8 7 6 5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.70 mL	13.52 mL	27.05 mL
5 mM	0.54 mL	2.70 mL	5.41 mL
10 mM	0.27 mL	1.35 mL	2.70 mL
50 mM	0.05 mL	0.27 mL	0.54 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 60 publications citing the usage of this product.

• Urwyler Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-MthD.-aspartate receptor antagonists - I. Pharmacological characterization in vitro. Neuropharmacology 1996 PMID: 8887974
• Urwyler Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-MthD.-aspartate receptor antagonists - II. Pharmacological characterization in vivo. Neuropharmacology 1996 PMID: 8887975
• Bakshi Disruption of prepulse inhibition and increases in locomotor activity by competitive N-MthD.-aspartate receptor antagonists in rats. J.Pharmacol.Exp.Ther. 1999 PMID: 9918570

Product Documents for SDZ 220-581